CML & PH+ All: There is so much more to know CML & PH+ All: There is so much more to know Explore

The think test treat programme was initiated by Incyte to raise awareness of the importance of regular and sensitive monitoring and mutation testing in patients with PH+ LEUKAEMIAS

Think

About how regular monitoring can help you identify patients
at risk and help guide your therapeutic treatment decisions 1-5

Test

For TKl-resistant mutations in CML patients with warning or failure, and when switching TKI , and in Ph+ ALL patients with persistent or increasing MRD 1,6-8

Treat

With the most appropriate
TKI according to mutation
testing results 1,6-10

Incyte is committed to making a difference in the way the community is monitoring and performing mutation testing for patients with CML & PH+ All

INCYTE INITIATED THE THINK TEST TREAT
PROGRAMME TO:

 

  • Identify and address barriers to optimal monitoring and mutation testing across Europe
  • Raise awareness and educate about how monitoring and sensitive mutation testing can guide clinical decision-making in CML and Ph+ ALL
  • Support research into different aspects of mutation testing

FIND OUT MORE WITH OUR EDUCATIONAL RESOURCES

For further information, please contact Incyte Medical Information: eumedinfo@incyte.com